Gary H Lyman1, Kim Allcott2, Jacob Garcia3, Scott Stryker3, Yanli Li3, Maureen T Reiner3, Derek Weycker4. 1. Fred Hutchinson Cancer Research Center and University of Washington, 1100 Fairview Avenue North, Seattle, WA, 98109, USA. glyman@fredhutch.org. 2. Oxford PharmaGenesis Ltd., Oxford, UK. 3. Amgen Inc., Thousand Oaks, CA, USA. 4. Policy Analysis Inc. (PAI), Brookline, MA, USA.
Abstract
PURPOSE: Granulocyte colony-stimulating factors (G-CSF) are commonly used in clinical practice to prevent febrile neutropenia (FN). US and EU prescribing information and treatment guidelines from the NCCN, ASCO, and EORTC specify that pegfilgrastim, a long-acting (LA) G-CSF, should be administered at least 24 h after myelosuppressive chemotherapy. Nevertheless, many patients receive LA G-CSFs on the same day as chemotherapy. This systematic literature review evaluated the relative merits of same-day versus next-day dosing of LA G-CSFs. METHODS: A broad Ovid MEDLINE® and Embase® literature search was conducted that examined all publications indexed before May 9, 2016 that compared same-day versus next-day LA G-CSF administration. A congress abstract literature search included congresses from January 1, 2011 to April 6, 2016. The parameters for this review were prospectively delineated in a research protocol and adhered to the PRISMA Guidelines. RESULTS: The first part of the systematic literature search identified 1736 publications. After elimination of duplicates, title/abstract screening was conducted on 1440 records, and full text review was conducted on 449 publications. Eleven publications met all criteria and are included in this systematic review; of these, four included data from randomized or single arm prospective studies, and seven were retrospective studies. In most studies included in this review and across a variety of tumor types, administration of pegfilgrastim at least 24 h after myelosuppressive chemotherapy resulted in improved patient outcomes. CONCLUSIONS: Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy.
PURPOSE: Granulocyte colony-stimulating factors (G-CSF) are commonly used in clinical practice to prevent febrile neutropenia (FN). US and EU prescribing information and treatment guidelines from the NCCN, ASCO, and EORTC specify that pegfilgrastim, a long-acting (LA) G-CSF, should be administered at least 24 h after myelosuppressive chemotherapy. Nevertheless, many patients receive LA G-CSFs on the same day as chemotherapy. This systematic literature review evaluated the relative merits of same-day versus next-day dosing of LA G-CSFs. METHODS: A broad Ovid MEDLINE® and Embase® literature search was conducted that examined all publications indexed before May 9, 2016 that compared same-day versus next-day LA G-CSF administration. A congress abstract literature search included congresses from January 1, 2011 to April 6, 2016. The parameters for this review were prospectively delineated in a research protocol and adhered to the PRISMA Guidelines. RESULTS: The first part of the systematic literature search identified 1736 publications. After elimination of duplicates, title/abstract screening was conducted on 1440 records, and full text review was conducted on 449 publications. Eleven publications met all criteria and are included in this systematic review; of these, four included data from randomized or single arm prospective studies, and seven were retrospective studies. In most studies included in this review and across a variety of tumor types, administration of pegfilgrastim at least 24 h after myelosuppressive chemotherapy resulted in improved patient outcomes. CONCLUSIONS: Data from multiple publications support administration of pegfilgrastim at least 1 day after chemotherapy.
Authors: Caroline C Billingsley; Samuel N Jacobson; Sarah M Crafton; Aleia K Crim; Quan Li; Erinn M Hade; David E Cohn; Jeffrey M Fowler; Larry J Copeland; Ritu Salani; Floor J Backes; David M O'Malley Journal: Int J Gynecol Cancer Date: 2015-09 Impact factor: 3.437
Authors: Georgia Kourlaba; Meletios A Dimopoulos; Dimitrios Pectasides; Dimosthenis V Skarlos; Helen Gogas; George Pentheroudakis; Angelos Koutras; George Fountzilas; Nikos Maniadakis Journal: Support Care Cancer Date: 2014-12-19 Impact factor: 3.603
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069
Authors: Jenny M Whitworth; Kellie S Matthews; Kimberly A Shipman; T Michael Numnum; James E Kendrick; Larry C Kilgore; J Michael Straughn Journal: Gynecol Oncol Date: 2008-12-24 Impact factor: 5.482
Authors: Reshma L Mahtani; Rajesh Belani; Jeffrey Crawford; David Dale; Lucy DeCosta; Prasad L Gawade; Chanh Huynh; Tatiana Lawrence; Sandra Lewis; William W MacLaughlin; Mohit Narang; Robert Rifkin Journal: Support Care Cancer Date: 2022-04-14 Impact factor: 3.603
Authors: Anna Thunström Salzer; Maria J Niemiec; Ava Hosseinzadeh; Marios Stylianou; Fredrik Åström; Marc Röhm; Clas Ahlm; Anders Wahlin; David Ermert; Constantin F Urban Journal: Front Immunol Date: 2018-09-11 Impact factor: 7.561